PMID- 18626271
OWN - NLM
STAT- MEDLINE
DCOM- 20081024
LR  - 20211020
IS  - 1533-712X (Electronic)
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 28
IP  - 4
DP  - 2008 Aug
TI  - Physiological and subjective responses to controlled oral 
      3,4-methylenedioxymethamphetamine administration.
PG  - 432-40
LID - 10.1097/JCP.0b013e31817ef470 [doi]
AB  - A randomized, within-subject, double-blind, inpatient study of the physiological 
      and subjective effects of oral 3,4-methylenedioxymethamphetamine (MDMA) was 
      conducted in human volunteers with previous MDMA experience. Placebo, low (1.0 
      mg/kg), and high (1.6 mg/kg) doses of oral MDMA were administered in a controlled 
      inpatient setting at least 7 days apart to 6 African American (4 male, 2 female) 
      and 2 white (both male) volunteers (mean [SE] age, 21.1 [0.8] years; weight, 77.2 
      [7.7] kg). 3,4-Methylenedioxymethamphetamine doses were 46 to 150 mg, in the 
      range of typical recreational doses. Participants completed all sessions without 
      clinically significant adverse events. 3,4-Methylenedioxymethamphetamine produced 
      significant dose-dependent increases in heart rate (highest, 132 bpm), systolic 
      (highest, 171 mm Hg) and diastolic (highest, 102 mm Hg) blood pressure, and 
      subjective responses for energy level, closeness to others, mind racing, 
      heightened senses, and high (evaluated by visual analog scales). Peak effects 
      occurred 1 to 2 hours after dose, with no secondary peak. There were no 
      significant effects on body temperature (measured at tympanic membrane), 
      respiratory rate, or blood oxygen saturation (by pulse oximetry). Although most 
      physiological and subjective parameters were significantly correlated with MDMA 
      plasma concentrations, correlation coefficients were low and clinically 
      insignificant, eliminating the ability to predict effects from single plasma 
      concentrations. These findings suggest that oral MDMA in typical recreational 
      doses produces short-term effects on cardiovascular function and subjective state 
      but that temperature effects may result from interaction with environmental and 
      subject factors.
FAU - Kolbrich, Erin A
AU  - Kolbrich EA
AD  - Chemistry and Drug Metabolism, Intramural Research Program, National Institute on 
      Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA.
FAU - Goodwin, Robert S
AU  - Goodwin RS
FAU - Gorelick, David A
AU  - Gorelick DA
FAU - Hayes, Robert J
AU  - Hayes RJ
FAU - Stein, Elliot A
AU  - Stein EA
FAU - Huestis, Marilyn A
AU  - Huestis MA
LA  - eng
GR  - NIH0011996773/ImNIH/Intramural NIH HHS/United States
GR  - Z01 DA000468-04/ImNIH/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Adrenergic Uptake Inhibitors)
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Administration, Oral
MH  - Adolescent
MH  - Adrenergic Uptake Inhibitors/administration & dosage/metabolism/*pharmacology
MH  - Adult
MH  - Body Temperature/drug effects/physiology
MH  - Cardiovascular Physiological Phenomena/*drug effects
MH  - Dose-Response Relationship, Drug
MH  - Double-Blind Method
MH  - Female
MH  - Hallucinogens/administration & dosage/metabolism/*pharmacology
MH  - Heart Rate/drug effects/physiology
MH  - Hemodynamics/*drug effects
MH  - Humans
MH  - Inpatients
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/administration & 
      dosage/metabolism/*pharmacology
MH  - Perception/*drug effects
MH  - Surveys and Questionnaires
PMC - PMC2587205
MID - NIHMS50281
EDAT- 2008/07/16 09:00
MHDA- 2008/10/25 09:00
PMCR- 2009/08/01
CRDT- 2008/07/16 09:00
PHST- 2008/07/16 09:00 [pubmed]
PHST- 2008/10/25 09:00 [medline]
PHST- 2008/07/16 09:00 [entrez]
PHST- 2009/08/01 00:00 [pmc-release]
AID - 00004714-200808000-00011 [pii]
AID - 10.1097/JCP.0b013e31817ef470 [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2008 Aug;28(4):432-40. doi: 10.1097/JCP.0b013e31817ef470.